Drug intelligence / Profile preview

LHD153R

Development stage: Phase 1
Lead developer: GSK
Administration: Intramuscular

Overview

LHD153R is a component used in vaccine formulations, specifically in combination with aluminium hydroxide and CRM197 protein for meningococcal C conjugate vaccines. It is involved in enhancing immune responses but specific details about its mechanism of action or primary indication are not provided in the available data.

Targets

TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on LHD153R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LHD153R.

Explore the full profile